CCU Molecular Hematology/Oncology - Clinical Research
Cancer of unknown primary (CUP) accounts for 2–5% of all malignancies, with 80–85% being of an unfavourable subset with extensive metastatic dissemination. There has been little progress in improving outcomes for patients with CUP. The unfavourable subset has a poor prognosis, with a median overall survival of less than 1 year when treated with the current standard of care (non-specific platinum-based chemotherapy), creating a high unmet medical need for new therapeutic approaches.